Fox Chase Cancer Center News

Fox Chase Researchers Uncover Achilles' Heel in Aggressive Breast Tumors

PHILADELPHIA (October 12, 2010) – In an unexpected twist, Fox Chase Cancer Center researchers find that the loss of a single protein, Nedd9, initially slows cancer formation but then makes the tumors that do arise more aggressive. The good news, though, is that the lack of Nedd9 also makes the aggressive tumors more sensitive to a class of drugs that are already used in the clinic.

VIEW STORY

Fox Chase Launches Prostate REACH Initiative to "Reach Out" to Men at High-Risk for Prostate Cancer

PHILADELPHIA (October 10, 2010) – Fox Chase Cancer Center has received a grant from The Philadelphia Foundation’s Lola E. Douglass and Margaret E. Demment funds to launch Prostate REACH, a new initiative aimed at making Fox Chase’s existing Prostate Cancer Risk Assessment Program more accessible to high-risk men through convenient community locations and patient navigation services. 

VIEW STORY

Local Student Raises Money for Cancer Research through Fox Chase's Charity Dog-Walk

PHILADELPHIA (October 10, 2010) – When it came time for Ariel Silverman, a 12-year-old Bat Mitzvah candidate from Upper Dublin, to choose her mitzvah project, the choice was clear. She decided to combine her love of dogs with her willingness to support cancer research by raising money for Fox Chase Cancer Center’s annual charity dog-walk—Paws for the Cause.

VIEW STORY

'Synthetic Lethality' Strategy Improves Molecularly Targeted Cancer Therapy

PHILADELPHIA (September 21, 2010) – Molecularly targeted therapies can reduce tumors rapidly. However, not all tumors respond to the drugs, and even those that do often develop resistance over time. Looking for a way to combat the problem of resistance, researchers at Fox Chase Cancer Center hypothesized that hitting already weakened cancer cells with a second targeted agent could kill them—but only if it was the right second agent.

VIEW STORY

Fox Chase Researchers Uncover Activation Signal for Aurora-A Oncogene: Discovery May Lead to More Potent Drug Combinations

PHILADELPHIA (September 7, 2010) - Aurora-A kinase (AurA) is an enzyme that is hyperactive in many cancers and drives tumor cell proliferation. Several AurA inhibitors are currently being tested in clinical trials to see if they slow tumor growth. Now, researchers in the Developmental Therapeutics Program at Fox Chase Cancer Center have identified an activation signal for AurA. 

VIEW STORY